Table 3 Impact of infiltration by various immune cell subtypes on disease-free survival (DFS)
| Â | Cut-off value* | DFS | p |
|---|---|---|---|
Immune cells in primary tumor | |||
CD3 | >3.04 (n = 16) vs. ≤ 3.04 (n = 16) | 85% vs. 67% | 0.4 |
CD8 | >2.49(n = 16) vs. ≤ 2.49(n = 16) | 79% vs. 69% | 0.29 |
FoxP3 | >1.81 (n = 17) vs. ≤ 1.81(n = 15) | 86% vs. 63% | 0.27 |
CD20 | >0.23 (n = 18) vs. ≤ 0.23(n = 13) | 83% vs. 81% | 0.8 |
CD68 | >1.02 (n = 16) vs. ≤ 1.02(n = 16) | 73% vs. 75% | 0.8 |
Granzyme B | >0 (n = 18) vs. = 0(n = 15) | 82% vs. 68% | 0.53 |
Intraepithelial immune cells in metastatic lymph nodes | |||
CD3 | >3.52 (n = 13) vs. ≤ 3.52 (n = 14) | 77% vs. 62% | 0.26 |
CD8 | >1.29 (n = 14) vs. ≤ 1.29 (n = 14) | 91% vs. 53% | 0.07 |
FoxP3 | >2.26 (n = 14) vs. ≤ 2.26 (n = 13) | 84% vs. 53% | 0.17 |
CD20 | >1.76 (n = 12) vs. ≤ 1.76 (n = 11) | 82% vs. 60% | 0.29 |
CD68 | >1.05 (n = 14) vs. ≤ 1.05 (n = 13) | 67% vs.73% | 0.9 |
Granzyme B | >0 (n = 11) vs. = 0(n = 19) | 80% vs. 68% | 0.46 |
Peritumoral immune cells in lymphatic tissue of metastatic nodes | |||
CD3 | >204.5 (n = 13) vs. ≤ 204.5 (n = 13) | 66.7% vs. 80.8% | 0.25 |
CD8 | > 37.5 (n = 12) vs. ≤ 37.5 (n = 12) | 72.7% vs. 76.4% | 0.53 |
FoxP3 | > 44 (n = 11) vs. ≤ 44 (n = 12) | 90.9% vs. 62.3% | 0.18 |
CD20 | > 192 (n = 11) vs. ≤ 192 (n = 11) | 100% vs. 63.6% | 0.039 |
CD68 | > 5.5 (n = 13) vs. ≤ 5.5 (n = 13) | 76.9% vs. 81.5% | 0.5 |
Granzyme B | >0 (n = 15) vs. = 0 (n = 15) | 78.6% vs.67.3% | 0.65 |
Immune cells in uninvolved regional lymph nodes | |||
CD3 | >183 (n = 15) vs. ≤ 183 (n = 16) | 75.0% vs. 73.3% | 0.675 |
CD8 | >88 (n = 15) vs. ≤ 88 (n = 16) | 84.6% vs. 65.6% | 0.337 |
FoxP3 | >49 (n = 15) vs. ≤ 49 (n = 16) | 78.6% vs. 71.1% | 0.905 |
CD20 | >147 (n = 15) vs. ≤ 147 (n = 16) | 79% vs. 68.6% | 0.779 |
CD68 | >4 (n = 12) vs. ≤ 4 (n = 17) | 75.8% vs. 68.8% | 0.424 |
Granzyme B | >0 (n = 13) vs. = 0 (n = 15) | 73.3% vs.68.8% | 0.939 |